Presented by
Management Forum

Pharmacovigilance

Understanding PhV today – a basic training course on the principles and practice of global PhV for those working in drug safety.

6-8 Dec 2021 + 3 more dates

Enrol now

  • Format: Live online, Classroom
  • CPD: 18 hours for your records
  • Certificate of completion

Course overview

This comprehensive three-day course has been designed to provide an introductory guide for all those concerned with pharmacovigilance. The interactive programme will cover topics from basic pharmacovigilance principles and terminologies through to the current regulatory framework and its global impact, including drug surveillance in the EU, US and Japan. Proactive pharmacovigilance pre- and post-marketing will be addressed as will risk management, the challenges of causality assessments and effective signal detection.

Our panel of experts will offer practical guidance throughout the course and use real-world examples and case studies to contribute to the development of your knowledge. There will also be ample opportunity to share experiences with the speakers and fellow professionals, which will further enhance your understanding of pharmacovigilance issues.

Key topics to be addressed include:

  • Principles of pharmacovigilance and data resources
  • Risk management, causality assessment and postauthorisation safety and efficacy studies (PASS/PAES)
  • Pharmacoepidemiological studies and evolution of periodic safety update reports (PSURs), periodic benefit-risk evaluation reports (PBRERs) and development safety update reports (DSURs)
  • Proactive pharmacovigilance pre- and post-marketing, risk-benefit assessment
  • Pharmacovigilance regulations, clinical trial ADR reporting requirements n Drug surveillance in countries outside Europe
  • Drug surveillance in countries outside Europe
  • Post-marketing surveillance: observational cohort studies
  • An overview of signal detection and risk management plans (RMPs)

Who should attend?

Anybody involved and interested in the daily practice of pharmacovigilance, including pharmaceutical physicians and those working in:

  • Drug safety
  • Adverse reaction monitoring
  • R&D
  • Regulatory affairs
  • Registration

Enrol now

The Pharmacovigilance course will cover:

Principles of pharmacovigilance and data resources

  • Basic principles of monitoring drug safety
  • An overview of methodology
  • Data resources available for monitoring and evaluating drug safety
  • Responding to drug safety signals

Risk management and risk minimisation: basic principles

  • Basic principles
  • Proactive strategies
  • Principles of risk minimisation
  • PASS and PAES

Causality assessment: clinical diagnosis of adverse events

  • The principles of causality assessment with practical examples
  • Medical evaluation of individual reports of adverse events
  • Strategies for follow-up

The current regulatory framework and its global impact

  • Overview of European regulatory framework, including 2012 EU pharmacovigilance legislation
  • Implications for the global environment – the links to ICH and CIOMS recommendations
  • Inspections and penalties for non-compliance
  • Practical applications of definitions

European post-marketing pharmacovigilance regulations

  • The role of the Pharmacovigilance Risk Assessment Committee (PRAC) and SCOPE initiative
  • Quality management systems and the pharmacovigilance system master file (PSMF)
  • QPPV
  • Expedited reporting: solicited vs spontaneous
  • Periodic reports and signal management and use of EudraVigilance
  • RMPs and risk minimisation
  • PASS/PAES
  • Additional monitoring
  • Pharmacovigilance inspections/audit
  • Public hearings including first EMA hearing – September 2017
  • Stakeholder involvement initiatives such as PROTECT, WEB-RADR
  • New electronic reporting standards, E2B (R3), IDMP

Proactive pharmacovigilance pre- and post-marketing

  • Anticipating drug safety issues in development of small molecules and biologics
  • What specific and non-specific safety monitoring should be done?
  • Handling safety signals in development
  • Differences between pre-marketing studies and post-marketing experience

Risk-benefit assessment

  • General principles
  • Quantifying risk
  • Taking action to optimise risk-benefit
  • Monitoring the effectiveness of risk management measures

Clinical trial ADR reporting requirements

  • ICH E2A and general requirements
  • Expedited reports
  • EU Clinical Trials Directive, Clinical Trial Regulation and detailed guidance
  • US IND requirements
  • DSURs

Pharmacoepidemiological studies – basic designs, strengths, weaknesses and examples

  • Real-world data is the king
  • Randomisation in the real world
  • Drugs and devices – it’s all ‘exposure’
  • Tracking all patients?

Periodic reporting – PSURs and PBRERs

  • Evolution of the PSUR, PBRER and DSUR
  • What do we submit and when to submit it
  • Practical aspects of compiling PSURs and PBRERs
  • Linking DSURs, RMPs, PSURs, PBRERs and core safety information

Drug surveillance in countries outside Europe

  • US culture
  • NDA and IND safety reporting
  • Inspections
  • Japan culture
  • Post-marketing safety surveillance programmes in Japan
  • Pharmacovigilance in other countries

Practicalities of signal detection

  • Definitions of signals
  • Regulatory guidances on signal detection by industry and regulators
  • Resources for signal detection
  • Quantitative vs qualitative signal detection

Examples of pharmacoepidemiological studies used in risk management

  • How we weigh evidence
  • Observational cohort studies
  • Case control studies
  • Drug registries (anti-TNFs)
  • Pregnancy registries

Practicalities of risk management

  • A real-world example of the development of a successful EU RMP
  • Requirements of RMPs from an industry point of view
  • How to write a successful RMP
  • Reporting results of outcomes of activities in the RMP
  • Updating a RMP

Practical pharmacovigilance workshop

  • A practical case study with valuable hands-on experience
  • Handling an important safety alert from regulators
  • Assessment of risk
  • Determining measures to respond to previously unidentified risks
  • Continuing assessment and communication of risk-benefit

Enrol now

Saad Shakir

Saad Shakir is Director of the Drug Safety Research Unit. After qualifying and working in Medicine he has been working in pharmacovigilance & pharmacoepidemiology for more than a decade, initially at the Medicines Control Agency (MCA) in the UK then within the Pharmaceutical Industry. He has worked and advised on many drug safety issues including product withdrawals and major safety hazards. He is an author of many publications in scientific journals on pharmacovigilance and pharmacoepidemiology and is a member of the editorial boards of the journals of Pharmacoepidemiology and Drug Safety.

More details

Shelley Gandhi

Shelley Gandhi joined NDA Group AB in 2012 and previously was with the MHRA (UK Regulatory Authority) for 19 years. She has extensive knowledge of all European regulatory processes relating to monitoring the safety of licensed medicinal products and ancillary devices and has investigated possible risks and has taken appropriate actions to minimise risk to public health through both European and National Committees.
She was Vigilance and Intelligence Research Group Unit Manager where she led a team of 30 whose primary role is to carry out risk assessment. In her final year at the MHRA, she mainly focussed on delivering the new pharmacovigilance legislation in Europe and ensuring the MHRA would be ready.
She is currently using this regulatory experience to work with industry to ensure they implement the new pharmacovigilance legislation.

More details

William Richardson

Bill Richardson is a Medical Assessor at NDA Group. He initially qualified in medicine and trained as an anaesthetist, before moving to the Pharmaceutical Industry, working for 15 years in Medical Affairs, Clinical Development, and Pharmacovigilance. He joined the Medicines Control Agency (now MHRA) in 2002 and had responsibility for monitoring the safety of “black triangle” products; signal generation and assessment; pharmacovigilance assessment for CHM, PRAC and CHMP; assessment of licence variations; assessment of Periodic Safety Update Reports and Risk Management Plans; and assessment of advertising.

More details

Seema Jaitly

Dr Seema Jaitly qualified in Medicine from Charing Cross and Westminster Medical School in 1992 and worked in hospital medicine for four years. She has worked in the pharma industry for over 18 years at CROs and companies spanning clinical research, medical affairs, pharmacovigilance and the EU QPPV role. In 2010 she founded Essjay Solutions to offer pharmacovigilance services, consultancy and contracting services.
She is currently studying for an MSc in epidemiology with the London School of Hygiene and Tropical Medicine.

More details

Glyn Belcher

Dr Glyn Belcher has over 25 years experience in clinical development and drug safety in the pharmaceutical industry. He qualified in medicine from Oxford and Cambridge and received his PhD in neuropharmacology from the latter university. After a number of years in hospital medicine he joined Schering and worked in clinical research in the UK affiliate before moving to headquarters in Berlin, first as head of cardiovascular clinical research and later as head of a new safety department covering clinical development activities. He then became Director of Clinical Drug Safety and EU QPPV for Takeda Europe and a global safety officer of Takeda headquarters in Osaka. His most recent position in the industry was Vice President of Drug Safety and Risk Management for all ex-USA territories of Biogen Idec and EU QPPV for the company. He now has his own consultancy company, PV Consultancy Ltd, and works with a number of companies in the areas of clinical development and drug safety, as well as undertaking an increasing commitment to teaching and training in these areas.

More details

John Parkinson

John Parkinson is a Data and Pharmaco-epidemiology Consultant. He previously worked as Director of the Clinical Practice Research Datalink (CPRD) at the MHRA, which developed out of the General Practice Research Database (GPRD) and NIHR Research Capability Programme. He has been instrumental in enabling record linkage of NHS data and of its wide use in the many aspects of pharmacoepidemiology as well as providing input to the pharmaceutical industry on studies and types of studies that companies may find helpful in their quest to make available effective and safe medicines

More details

Ian Douglas

Professor Ian Douglas is an epidemiologist, currently funded by an MRC Methodology Fellowship. He initially studied physiology and completed a PhD in Manchester. Since then he has spent several years at the UK Medicines & Healthcare Products Regulatory Agency and in the pharmaceutcial industry investigating adverse effects of drugs – both in clinical trials and post-marketing. He completed the MSc in epidemiology at LSHTM in 2005. He is the course organiser for the LSHTM Certificate Course in Pharmacoepidemiology and Pharmacovigilance.
His research interests are primarily in pharmacoepidemiology, and in particular, how we can use large primary care databases to investigate the effects of drugs – both harmful and beneficial. He is exploring methodologies to minimise some of the biases inherent in the research of drug effects, and main current areas of interest are case-only approaches to study design and the use of propensity scores. He is also a member of the UK Medicines and Healthcare Products Regulatory Agency’s Pharmacovigilance Expert Advisory Group.

More details

Book Pharmacovigilance Live online/Classroom training

6-8 Dec 2021

Live online

09:00-17:00 UK (London) (UTC+00)
10:00-18:00 Paris (UTC+01)
04:00-12:00 New York (UTC-05)
Course code 11088

  • GBP 1,249 1,549
  • EUR 1,595 2,015
  • USD 1,857 2,325

Until 01 Nov

View basket 

21-23 Jun 2022

Live online

00:00-00:00 UK (London) (UTC+01)
01:00-01:00 Paris (UTC+02)
19:00-19:00 New York (UTC-04)
Course code 11923

  • GBP 1,249 1,549
  • EUR 1,595 2,015
  • USD 1,857 2,325

Until 17 May

View basket 

20-22 Sep 2022

Classroom
London venue TBC

09:00-17:15 UK (London)
Course code 11664

  • GBP 1,549 1,849
  • EUR 2,169 2,589
  • USD 2,416 2,884

Until 16 Aug

  • 3 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

View basket 

14-16 Dec 2022

Live online

00:00-00:00 UK (London) (UTC+00)
01:00-01:00 Paris (UTC+01)
19:00-19:00 New York (UTC-05)
Course code 11924

  • GBP 1,249 1,549
  • EUR 1,595 2,015
  • USD 1,857 2,325

Until 09 Nov

View basket 

Reviews of IPI's Pharmacovigilance training course


Very informative and great 3 days.

Jun 21 2021

Paul Byrne
Deputy QPPV, Nelsons

Dec 2 2019

I loved the course and it was amazing to be taught by people who are very experienced in the topics and be able to get their insights and hear their experiences.

Tina Tayebi
Pharmacovigilance Associate, Diamond Pharma Services

Jun 24 2019

The course was very well organised and useful. The choice of speakers was very good and balanced. Overall, I was very happy with the course.

Karl Pauls
Medical advisor, Centre for epidemiology and health research (ZEG)

Jun 24 2019

Workshop is very good because you have to USE the knowledge you gain. Interaction between speaker and attendees is very good too!

Anna Bøgelund Møller
Pharmacovigilance scientist, Larix

Jun 24 2019

The course gave overall understanding on pharmacovigilance. The presentations were clear and with helpful examples. Interaction between participants and speakers was great. All the speakers have good experiences and knowledge.

Teodora Crowe-Wijasa
Consultant Medical Safety Physician, DADA Consultancy BV

Jun 24 2019

Obviously all speakers have huge experiences within the PV processes.

Haiping Ma
Senior Safety Quality Professional, Novo Nordisk A/S

Dec 3 2018

Expert presenters with engaging and thoughtful presentations that allow plenty of time for questions and discussion. All very knowledgeable and engaging.

Sam Allen
Drug Safety Operations Medic, Mundipharma Research Ltd.

Dec 3 2018

My overall opinion is very positive, I am not disappointed at all. Speakers did a very good job - being approachable, giving examples, sharing his/her professional experiences, etc. Very knowledgeable speakers with relevant experience.

Vania Horta
Drug Safety & Information Officer , Wockhardt UK Limited

Dec 3 2018

Co-ordinators were great, material provided was concise and well presented. Time for breaks and lunches were spot on. Most of the speakers were excellent. I have 18 months experience in PV and I felt like the course was at my level. This course is not suitable for beginners.

Bhupesh Panchal
Drug Safety & Information Officer, Wockhardt UK Limited

Dec 3 2018

Amazing speakers with a wealth of knowledge and experience.

Dalal Abdulaziz
Regulatory Manager, Al Hafez Trading Est

Jun 19 2018

A greatly organised and informative course given by driven and well informed speakers.

Willem van Lierop
Senior Drug Safety employee, ApotheekZorg

Jun 19 2018

Exactly what we need. Very good.

Gabriel Georgescu
Regulatory Affairs Manager, Ewopharma AG

Dec 4 2017

Enjoyed the course. Although quite intense in the number of topics, it was well organized and stuck only to the important things. Would recommend and am thinking about continuing to The advanced PV one.

Marta Telebar
PV Project Specialist, Arriello s.r.o.

Dec 4 2017

The course was very useful and interesting to me personally

Darya Pospíšilová
Pharmacovigilance Project Manager, Arriello

Jun 20 2017

I was happy about the location, the presenters and the organizers for this course

Abdullah Al Dawood
QPPV and Regulatory Affairs Supervisor , Apotex Saudi Arabia

Jun 20 2017

The course was well structured and covered all important aspects of PV. Everything was presented in clear presentations with helpful examples. Interactions between participants and speakers was easy and helpful.

Birte Hofmann
Director Pharmacokinetics Expert, Bayer AG

Dec 4 2017

All the speakers are knowledgable and have good experience

Negin Goudarz
Pharmacovigilance Associate , Emas Pharma Ltd

Dec 4 2017

Very nice and informative course, very satisfied

Birgitte Wolf
Senior Safety Specialist , LEO Pharma

Jun 20 2017

Found the content delivered from the speakers very good.

Priya Cutts
Report Specialist, Procter and Gamble Technical Centres Ltd

Dec 6 2016

Well organised and the speakers were very knowledgeable

Claire McLaughlin
Drug Safety Specialist, Kyowa Kirin International

Dec 6 2016

Excellent. Very good speakers and interactions.

Susanne Mathias
Senior GCP Advisor Specialist, Novo Nordisk A/S

Dec 6 2016

Very passionate speakers

Sabrina Montante
Safety Scientist, GlaxoSmithKline

Dec 6 2016

It was very good, I had a great time

Camille Soulet
Vigilances Training Officer, Pierre Fabre

Jun 20 2016

It was a comprehensive, professional course, well organized and beneficial

Liron Weisman
Pharmacovigilance Compliance Associate, Teva Pharmaceuticals Industries Ltd

Jun 20 2016

Very nice course which provides good instruction into PV and overall picture of PV requirements/obligations

Oresta Makaruha Stegic
FDF RA manager, xellia

Dec 6 2016

High level training with great speakers, very good welcome and accommodation

Camille Soulet
Vigilances Training Officer, Pierre Fabre

Dec 6 2016

I feel this course gives a good amount of information and is presented well. The speakers are very knowledgeable

Lee Rolfe
Actavis plc

Dec 6 2016

Overall I found the course to be very informative. Not only did I learn new information, but it helped me realise how much information I have picked up through my short time working in the industry and it reinforced this knowledge. I liked that there were a number of different speakers from different backgrounds who effectively cover different aspects of the topic in depth.

Sarah Bruce
Pharmacovigilance Officer, Kyowa Kirin

Dec 6 2016

I think the course and its content were very well run and I would be happy to attend another course by Management Forum

Lee Rolfe
Actavis plc

Jun 20 2016

Informative and well-organised but quite heavy going in parts

Gemma Anthony
PV & Regulatory Administrator, Meda Pharma Ltd

UK

  • 2Health Limited
  • Actavis plc
  • Actelion Pharmaceuticals
  • ADAMAS Consulting
  • Adamas Consulting Ltd
  • Alcon Laboratories (UK) Ltd
  • Allergan UK Limited
  • Antisoma Research Ltd
  • Arrow No.7 Limited
  • Aspar Pharmaceuticals Ltd
  • AstraZeneca
  • AstraZeneca R&D Charnwood
  • AstraZeneca UK Ltd
  • Auden McKenzie Group
  • Avecia Biotechnology Ltd
  • Bell's Healthcare
  • Bells Healthcare
  • Biogen IDEC Ltd
  • British American Tobacco Ltd
  • Brown & Burk UK Ltd
  • BTG International Ltd
  • Cambridge Healthcare Supplies Ltd
  • Celgene Europe Ltd
  • Cephalon (UK) Limited
  • Cephalon UK Ltd
  • Chiesi Limited
  • Chiltern International
  • Chugai Pharma Europe Ltd
  • City University, London
  • Clinigen
  • Cmed Clinical Research Services Ltd
  • Cycle Pharmaceuticals
  • DAIICHI PHARMACEUTICALS UK LTD
  • Daiichi Sankyo UK Ltd
  • Dannika Consulting Ltd
  • Department of Health
  • Diamond Pharma Services
  • DR REDDYS LABORATORIES (UK) LTD
  • Eisai Europe Limited
  • Eisai Limited
  • Eisai Ltd
  • Eli Lilly & Co Ltd
  • Eli Lilly & Company Limited/Elanco Animal Health
  • Emas Pharma Ltd
  • Epic Database Research Company Ltd
  • European Medicines Agency
  • Ewopharma International s.r.o.
  • Ferring Pharmaceuticals Ltd
  • Genus Pharmaceuticals Ltd
  • GlaxoSmithKline
  • GlaxoSmithKline Services Unlimited
  • GMClinical
  • GW Pharmaceuticals
  • GW Pharmaceuticals Limited
  • GW Pharmaceuticals Ltd
  • Harefield Pharmacovigilance Ltd
  • Hospira UK Limited
  • Hospira UK Ltd
  • Idis Limited
  • Immunocore Limited
  • Immunocore Ltd
  • IMS HEALTH LTD
  • IMS Health UK
  • INVERNESS MEDICAL INNOVATIONS LTD
  • Ipsen Biopharm Ltd
  • Janssen-Cilag Ltd
  • JensonR+ Limited
  • Kyowa Kirin
  • Kyowa Kirin International
  • M&A Pharmachem
  • Marlborough Pharmaceuticals Ltd
  • Martindale Pharma
  • Meda Pharma Ltd
  • Meda Pharmaceuticals Limited
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medtronic Ltd
  • Merck Pharmaceuticals Limited
  • Merck Sharp & Dohme Ltd
  • Mitsubishi Tanabe Pharma Europe
  • Mundi Pharma Int Ltd
  • Mundipharma Research Ltd
  • Mundipharma Research Ltd.
  • NDA Regulatory Science Ltd
  • Nelsons
  • Nicoventures Ltd
  • Norgine Ltd
  • Novartis Pharmaceuticals UK Ltd
  • Novatis Animal Health UK Ltd
  • Novo Nordisk Ltd
  • Octapharma Ltd
  • OMNICARE CLINICAL RESEARCH LTD
  • Oracle Corporation UK Ltd
  • Oxford Biomedica
  • PAGB (The Proprietary Association of Great Britain)
  • PAION UK Ltd
  • Parexel International Ltd
  • Perkin Elmer LAS (UK) Ltd
  • Piramal Healthcare Ltd
  • Procter & Gamble
  • Procter & Gamble Technical Centres Ltd
  • Procter and Gamble Technical Centres Ltd
  • ProductLife Group
  • ProductLife Limited
  • Profile Pharma
  • Public Health England
  • Pure Drug Safety Ltd
  • QA Pharmaceutical Services
  • RANBAXY EUROPE LTD
  • Reckitt Benckiser
  • RECORDATI PHARMACEUTICALS LTD
  • Regional QC Laboratory
  • Roche Products Ltd
  • Rosemont Pharmaceuticals
  • Rosemont Pharmaceuticals Limited
  • Rotapharm Ltd
  • SCHERING HEALTH CARE LTD
  • SCHWARZ PHARMA LTD
  • Scottish National Blood Transfusion Service
  • SEQ Limited
  • Servier R&D Ltd
  • Shire Pharmaceutical Ltd
  • South Devon Healthcare NHSTrust
  • SPMSD
  • Stiefel Laboratories
  • Stiefel Labs (UK) Limited
  • Strakan Pharmaceuticals, Prostrakan Limited
  • Sunovion Pharmaceuticals Europe Ltd
  • Swedish Orphan Biovitrum
  • Takeda Development Centre Europe Ltd
  • Takeda UK Limited
  • Teva UK Limited
  • The Mentholatum Company
  • Thornton & Ross Ltd
  • Toray Industries Inc
  • Torbay and South Devon NHS Trust
  • Trac Services Ltd
  • UCB Celltech
  • UCB Pharma Limited
  • Unilever
  • United Therapeutics Europe Ltd
  • University of Bradford
  • University of London
  • Veriton Pharma
  • Warner Chilcott Pharmaceuticals UK Ltd
  • Weleda
  • Winthrop Pharmaceuticals UK Ltd
  • Wise Pharmacies Limited
  • Wockhardt UK Limited
  • Wyeth Europa Ltd
  • Wyeth Pharmaceuticals
  • Zanza Laboratories Ltd

Switzerland

  • Actelion Pharmaceutical Ltd
  • Actelion Pharmaceuticals Ltd
  • Actelion Pharmaceuticals Ltd.
  • F. Hoffmann La Roche
  • F. Hoffmann-La Roche Ltd
  • Geistlich Pharma
  • Ginsana SA
  • Helsinn Healthcare S.A.
  • IBSA Institut Biochimique SA
  • Nestle Research Centre
  • NNIT A/S
  • Novartis Consumer Health SA
  • Novartis International AG
  • Novartis Pharma AG
  • Roche
  • Roche Pharma (Schweiz) AG
  • Roche Pharma (Switzerland) Ltd
  • SkyePharma AG
  • Speedel
  • SWISS REINSURANCE COMPANY
  • Swiss Tropical Institute
  • United Biosource Corporation
  • Universitätsspital Basel/ Department Klinische Forschung
  • Vifor SA

Netherlands

  • Apotheekzorg
  • ApotheekZorg Sittard
  • Astellas BV
  • Astellas Pharma Europe BV
  • Aurobindo Pharma BV
  • Bilthoven Biologicals BV
  • Celgene B.V
  • Centrafarm Pharmaceuticals BV
  • DADA Consultancy BV
  • Genzyme Europe BV
  • HAL Allergy BV Leiden
  • Julius Clinical Research
  • Leyden Delta bv
  • Merck BV
  • Merck Sharp & Dohme
  • N.V. Organon
  • Synthon Biopharmaceuticals BV

Germany

  • ABBOTT GmbH & Co KG
  • Abbott Laboratories GmbH
  • Abbott Products GmbH
  • Bavarian Nordic GmbH
  • Bayer AG
  • Bayer Pharma AG
  • Centre for epidemiology and health research (ZEG)
  • Dr Willmar Schwabe GmbH & Co
  • Fresenius Kabi Deutschland GmbH
  • Linde
  • Medac GmbH
  • Merck KGaA
  • Mundipharma Research GmbH & Co Kg
  • Mylan Healthcare GmbH
  • Solvay Deutschland GmbH
  • Takeda GmbH

Belgium

  • 4 Clinics
  • Baxter R&D Europe
  • Bristol-Myers Squibb SA
  • Colgate Palmolive Research & Development Inc
  • Colgate-Palmolive R&D
  • Glaxo Smithkline Biologicals
  • GlaxoSmithKline
  • GlaxoSmithKline Vaccines
  • Guerbet
  • Janssen Pharmaceutica NV
  • Oystershell NV
  • Sanofi-Aventis
  • SGS Belgium NV
  • SGS Belgium NV Life Science Services
  • UCB Pharma SA

France

  • Aeras Global TB Vaccine Foundation
  • Air Liquide Santé International
  • AnticipSante SAS
  • DBV Technologies
  • Guerbet
  • Johnson & Johnson
  • LFB Biotechnologies
  • Pierre Fabre
  • Pierre Fabre Medicament
  • Sanofi Pasteur MSD
  • Sanofi Pasteur Siege mondial
  • Sanofi-Synthelabo Groupe
  • Schering-Plough

Denmark

  • Ferring Pharmaceuticals
  • Ferring Pharmaceuticals A/S
  • Ferring Pharmaceuticals.
  • H. Lundbeck A/S
  • Larix
  • LEO Pharma
  • Leo Pharma A/S
  • MERCK SHARP & DOHME
  • Novo Nordish A/S
  • Novo Nordisk
  • Novo Nordisk A/S

Spain

  • Faes Farma S.A.
  • Faes Farma SA
  • FERRER INTERNACIONAL S.A.
  • Grupo Ferrer Internacional SA
  • Grupo Ferrer Internaional S.A.
  • Laboratorios Almirall S A
  • Laboratorios Leti SL Unipersonal
  • PHARMACIA SPAIN
  • Reig Jofre Group

Ireland

  • Athlone Laboratories
  • Ferring Ireland Ltd
  • Irotec Laboratories
  • Kora Healthcare
  • NorthStar Healthcare Ltd
  • Pfizer Limited
  • Pinewood Healthcare Limited
  • Pinewood Healthcare Ltd.

Israel

  • Gsap Medlogic
  • Kamada Ltd
  • Maccabi Health Services
  • Maccabi Healthcare Services
  • Teva Pharm Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Industries Ltd

Czech Republic

  • Arriello
  • Arriello s.r.o.
  • Baxter Czech spol. S r.o.
  • Teva Czech Industries S R O
  • Zentiva Group AS
  • Zentiva, k.s.

Sweden

  • AstraZeneca
  • Astrazeneca R&D
  • Clean Chemical Sweden AB
  • Q-Med AB
  • Sanofi-aventis AB
  • SOBI

United States of America

  • Abbott Laboratories
  • Aeras Global TB Vaccine Foundation
  • C.B. FLEET COMPANY INC
  • Jazz Pharmaceuticals Inc
  • Next Generation Clinical Research
  • Santen

Russia

  • Amgen LLC
  • Evrokontakt Plus
  • Pfizer Innovation LLC
  • Roche Moscow Ltd.
  • Voyage Tour LLC

Saudi Arabia

  • Al Faisaliah Medical Systems
  • Apotex Saudi Arabia
  • SAUDI FOOD & DRUG AUTHORITY
  • Saudi Food and Drug Authority
  • SFH

Croatia

  • Agency for Medicinal Products and Medical Devices of Croatia
  • Europharma doo
  • Pliva Hrvatska D.O.O.
  • xellia

Italy

  • AstraZeneca SPA
  • Chiesi Farmaceutici SPA
  • Recordati
  • Warner Chilcott Italy Srl

Austria

  • Baxter Innovations GmbH
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Octapharma Pharmazeutika Produktionsges.m.b.H.

Romania

  • Ewopharma AG
  • Romastru Trading Srl
  • Worwag Pharma GmbH & Co. KG

Slovenia

  • Blood Transfusion Centre of Slovenia
  • LEK Pharmaceuticals d.d.
  • Medis, d.o.o

Canada

  • ApoPharma Inc
  • Aspreva Pharmaceuticals Corporation

Finland

  • Orion Corporation Orion Pharma
  • OY LEIRAS FINLAND AB

Lithuania

  • Acorus Calamus
  • UAB Sicor Biotech

Norway

  • Pronova BioPharma Norge AS
  • Targovax ASA

Serbia

  • Medicines and Medical Devices Agency of Serbia
  • Poslovni centar Hemofarm

Slovak Republic

  • Ewopharma International s.r.o
  • Ewopharma International, s.r.o.

Albania

  • Promed

Algeria

  • AVENTIS PHARMA

Argentina

  • Seqirus

Brazil

  • Natura Inovacao Tecnologia de Produtos Ltda.

Bulgaria

  • ACTAVIS EAD

Estonia

  • Vitale-XD Ltd

Greece

  • AstraZeneca SA

India

  • DR Reddys Laboratories Ltd

Iran

  • Cobel Darou

Iraq

  • United Nations

Japan

  • Clinipace Wordwide

Korea, Democratic People's Republic Of

  • Archigen Biotech Limited

Korea, Republic Of

  • Korea Food & Drug Administration

Kuwait

  • Al Hafez Trading Est

Moldova

  • Balkan Pharmaceuticals

Taiwan

  • Taiwan Drug Relief Foundation

Turkey

  • Novo Nordisk

Ukraine

  • Schering-Plough CE AG

Enrol now

Multiple colleagues?
Talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy